Form 4: Bio-Rad EVP Evran Reports RSU Vesting & Stock Sale

Sedat Evran, EVP of Global Supply Chain at Bio-Rad Laboratories, reported the vesting of 1,044 restricted stock units and the subsequent sale of 335 shares for tax obligations.

Summary

• Sedat Evran, EVP, Global Supply Chain at Bio-Rad Laboratories, Inc., reported transactions involving the company's Class A Common Stock.
• On October 20, 2025, 1,044 shares of Class A common stock were acquired due to the vesting of restricted stock units (RSUs).
• Concurrently, 335 shares of Class A common stock were disposed of at a price of $321.9 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Sedat Evran directly beneficially owns 2,232.847 shares of Bio-Rad A Common Stock.
• The reporting person also holds 2,088 derivative securities in the form of restricted stock units.
• The original grant of 4,176 restricted stock units occurred on October 20, 2023, with vesting scheduled in four equal annual installments.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (RSU vesting) and a standard tax-related stock sale. It is a neutral to slightly positive event as it indicates the realization of compensation for an executive, reflecting ongoing employment and compensation structure.

Positives

• Vesting of 1,044 restricted stock units indicates a portion of executive compensation has been realized.
• The transaction reflects a standard compensation structure for executives.

Negatives

• The disposition of 335 shares reduces the direct beneficial ownership, though this is a routine sale for tax purposes.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The remaining 2,088 restricted stock units are expected to vest in future annual installments, as the original grant of 4,176 units on October 20, 2023, vests in four equal annual installments.

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitor analysis. It reflects standard executive compensation practices within the life sciences and diagnostics industry.

Comparison to Industry Standards

• The RSU vesting and subsequent sale for tax withholding are standard practices for executive compensation in publicly traded companies across various industries, including the life sciences sector. No specific comparable companies or projects are detailed in this filing.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock ownership and compensation realization, which is generally positive for corporate governance. The routine nature of the transaction is unlikely to have a significant direct impact on share price.
• Employees: Reflects the company's executive compensation practices.

Next Steps

• Future annual installments of the remaining 2,088 restricted stock units are expected to vest.

Key Dates

Keywords

Bio-Rad Laboratories, BIO, BIO.B, Sedat Evran, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Transaction, Supply Chain EVP